Status:
NOT_YET_RECRUITING
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Lead Sponsor:
Stanford University
Conditions:
Non Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.
Eligibility Criteria
Inclusion
- \>/= 18 years-old
- Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or
- Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers
- \>/= 6 months from the date of CAR-T infusion
- Fluent in English
- Able to attend and participate in in-person testing (Arm I)
- Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II)
Exclusion
- Concurrent enrollment in a CAR-T therapeutics research study
- Unable to be present for the scheduled testing
- Unable to participate in testing due to severe cognitive or physical limitation
- Actively receiving chemotherapy
- Progressive cancer
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05416554
Start Date
December 1 2025
End Date
December 1 2027
Last Update
February 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Cancer Center
San Francisco, California, United States, 94305